News
First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
16 May 24
Government, Regulations
First Wave BioPharma Announces ~$1.1M Registered Direct Offering Of 366,000 Shares Of Common Stock At A Price Of $2.95/Share, Priced At The Market
10 May 24
News, Offerings
HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
25 Mar 24
News, Initiation, Analyst Ratings
Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
15 Mar 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Mar 24
Movers
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease
14 Mar 24
Biotech, M&A, News, Health Care, General
12 Health Care Stocks Moving In Monday's Intraday Session
4 Mar 24
Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 Mar 24
Movers
First Wave BioPharma, Inc. To Raise ~$4M Of Gross Proceeds In Registered Direct Offering Of 525,625 Shares Of Common Stock At A Price Of $7.61 Per Share
4 Mar 24
News, Offerings
Press releases
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 May 24
Biotech, News, Press Releases, General
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20 May 24
Health Care, Press Releases
First Wave BioPharma Changes Name to Entero Therapeutics
16 May 24
Press Releases
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
10 May 24
Biotech, Press Releases, General
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
17 Apr 24
Biotech, News, Health Care, Press Releases, General
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
14 Mar 24
Biotech, M&A, News, Press Releases, General
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
4 Mar 24
Biotech, News, Financing, Press Releases, General